drugset / Trial / NCT06575738

Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents

NCT06575738

RandomizedParallel-groupSingle-blindTreatment

Summary

The study plans to learn more about what happens to the body after bariatric surgery in people 12 to 24 years old. The study aims to understand why people respond differently to bariatric surgery and how to define success beyond weight loss alone. The study also plans to learn more about whether a medication (semaglutide or tirzepatide) can help people 12 to 24 years old who, between 6 and 24 months after bariatric surgery, have not lost as much weight as expected.

Timeline

Start
2024-10-11
Primary completion
2027-09-01
Completion
2027-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Semaglutide Peptide 2.4 mg Subcutaneous
Subject Tirzepatide Peptide 15 mg Subcutaneous

Indications